The company has not filed an annual or quarterly report since its Q1 FY2020 10-Q, filed May 11, 2020. Its latest SEC filing is a 15-12B from Jul 13, 2020.
10-Q for Q1 FY2020, filed May 11, 2020
The sections below describe the company as of the FY2019 annual report.
Sells Andexxa, marketed in Europe as Ondexxya, to hospitals for reversing certain blood thinners in life-threatening or uncontrolled bleeding; develops cerdulatinib for blood cancers.
10-K for FY2019, filed Feb 28, 2020Our lead product is Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo] which we are marketing under the brand name of Ondexxya…View ↗
Cerdulatinib is our investigational SYK and Janus kinase ("JAK") inhibitor that uniquely inhibits two key cell signaling pathways…View ↗
Our products are purchased in the United States and Europe primarily by hospitals. U.S. hospitals purchase our products through a network…View ↗
Hospitals and distributors buy the medicines in one-time product sales; collaboration partners pay for research, clinical supply and licenses over time, and some agreements also provide milestone payments or royalties tied to sales.
10-K for FY2019, filed Feb 28, 2020Year Ended December 31, 2019 Year Ended December 31, 2018 Product Revenue, net Collaboration and License Revenue Total Product Revenue, net…View ↗
To date, our sources of product revenue have been from the U.S. sales of Andexxa and Bevyxxa, which we began shipping to customers in May…View ↗
In January 2014, we entered into an agreement with BMS and Pfizer to further study Andexxa as a reversal agent for their jointly-owned…View ↗
Sales-based royalties, including milestone payments based on the level of sales, related to license arrangements are excluded from variable…View ↗
$116.6M
10-K for FY2019, filed Feb 29, 2020
$116.6M ↗
Hospitals are the main buyers in the U.S. and Europe. U.S. hospitals buy through specialty and wholesale distributors; European hospitals buy directly from Portola or, less often, through distributors.
10-K for FY2019, filed Feb 28, 2020
No. It lost $290.7M in FY2019.
10-K for FY2019, filed Feb 29, 2020
−$271.3MView ↗
10-K for FY2019, filed Feb 29, 2020
−$290.7MView ↗
10-K for FY2019, filed Feb 29, 2020
−$239.5MView ↗
10-Q for Q1 FY2020, filed May 12, 2020
−$68.8MView ↗
8-K, filed Jul 2, 2020
As described in the Introductory Note above, on July 2, 2020, Purchaser irrevocably accepted for payment all Shares validly tendered and…View ↗
8-K, filed Jun 17, 2020
Pursuant to the terms of the Agreement, the termination became effective on June 12, 2020 and the parties will work together to unwind the…View ↗
Grew. Revenue grew 3.3x in 3 years, from $35.5M in FY2016 to $116.6M in FY2019, about 49% a year.
Andexxa moved to market
Andexanet alfa was a development program in the older report; the latest report describes U.S. and European approvals and commercial launches as Andexxa and Ondexxya.
10-K for FY2016, filed Mar 1, 2017 10-K for FY2019, filed Feb 28, 2020Andexxa is approved by the FDA as a reversal agent for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation is…View ↗
In the U.S., we initially received approval from the FDA in May 2018 to market product manufactured under our Gen 1 process using the…View ↗
Andexanet alfa received conditional approval under the brand name Ondexxya by the EC on April 26, 2019. This conditional approval included…View ↗
We completed our first sales of Ondexxya in Europe in July 2019 and are executing a phased launch of Ondexxya in Europe, with an initial…View ↗
Competes with Chugai Pharmaceutical, F. Hoffmann-LaRoche, Genentech, Gilead Sciences, Seattle Genetics, Takeda, Bayer, Verastem, Celgene, Spectrum Pharmaceuticals, and Kyowa Hakko Kirin
10-K for FY2019, filed Feb 28, 2020In the market for the treatment of FL, PTCL and CTCL, cerdulatinib, if approved, will compete with existing therapies (used as a single…View ↗
Loading...
